GlucoTune: A Unified Framework for Blood Glucose Preprocessing, Forecasting, and Benchmarking in Diabetes

Preprocessing blood glucose time-series data is a critical yet often overlooked step in developing data-driven methods for diabetes management, particularly for type 1 diabetes. The lack of standardized preprocessing workflows and evaluation protocols hinders reproducibility and complicates fair comparison across studies. These challenges are further exacerbated by data-sharing restrictions, as privacy and licensing constraints often prevent the redistribution of preprocessed medical datasets. To address these limitations, we present GlucoTune, a comprehensive and extensible framework for reproducible experimentation with blood glucose time-series data. The framework standardizes the entire experimental workflow, from preprocessing to model evaluation, enabling reproducible experiments directly from the original datasets. Reproducible preprocessing is achieved through configurable pipelines defined in portable YAML configuration files, ensuring consistent data handling without distributing sensitive preprocessed data. Beyond preprocessing, GlucoTune provides a unified interface for implementing, training, and evaluating blood glucose prediction models. The framework integrates public datasets through standardized wrappers and provides a curated collection of state-of-the-art blood glucose prediction and general time-series forecasting methods, while remaining readily extensible to additional datasets, preprocessing strategies, and forecasting models. To promote transparent and consistent evaluation, GlucoTune includes a benchmarking leaderboard that reports results across datasets, preprocessing configurations, and forecasting methods, enabling systematic comparison of experimental settings. We demonstrate the effectiveness of GlucoTune through comprehensive experiments and assess its usability in a user study.

Subject-Conditioned Glucose Forecasting in Type-1 Diabetes

Accurate forecasting of blood glucose concentration is key in the management of Type 1 Diabetes, facilitating early detection of adverse glycemic events and supporting timely therapeutic interventions. Despite recent advances in glucose prediction, most existing approaches rely on population-level representations or implicit personalization strategies that fail to deliver effective subject-specific forecasts. In this work, we propose Subject-Conditioned Glucose Prediction (SCGP), a novel multimodal deep learning architecture conceived for personalized blood glucose prediction. SCGP conditions glucose predictions based on observed glucose data and a compact subject-specific representation learned from contextual information. By explicitly separating subject characterization from glucose dynamics modeling and avoiding early fusion of heterogeneous inputs, the proposed framework effectively captures inter-subject variability while preserving robust and reliable temporal modeling. Experiments on two state-of-the-art benchmark datasets demonstrate that SCGP consistently improves forecasting performance, enabling reliable detection of adverse glycemic events across multiple prediction horizons, highlighting the benefits of explicit subject conditioning for personalized diabetes management.

Tailoring Adverse Event Prediction in Type 1 Diabetes with Patient-Specific Deep Learning Models

Effective management of Type 1 Diabetes requires continuous glucose monitoring and precise insulin adjustments to prevent hyperglycemia and hypoglycemia. With the growing adoption of wearable glucose monitors and mobile health applications, accurate blood glucose prediction is essential for enhancing automated insulin delivery and decision-support systems. This paper presents a deep learning-based approach for personalized blood glucose prediction, leveraging patient-specific data to improve prediction accuracy and responsiveness in real-world scenarios. Unlike traditional generalized models, our method accounts for individual variability, enabling more effective subject-specific predictions. We compare Leave-One-Subject-Out Cross-Validation with a fine-tuning strategy to evaluate their ability to model patient-specific dynamics. Results show that personalized models significantly improve the prediction of adverse events, enabling more precise and timely interventions in real-world scenarios. To assess the impact of patient-specific data, we conduct experiments comparing a multimodal, patient-specific approach against traditional CGM-only methods. Additionally, we perform an ablation study to investigate model performance with progressively smaller training sets, identifying the minimum data required for effective personalization-an essential consideration for real-world applications where extensive data collection is often challenging. Our findings underscore the potential of adaptive, personalized glucose prediction models for advancing next-generation diabetes management, particularly in wearable and mobile health platforms, enhancing consumer-oriented diabetes care solutions.

Lightweight Sequential Transformers for Blood Glucose Level Prediction in Type-1 Diabetes

Type 1 Diabetes (T1D) affects millions worldwide, requiring continuous monitoring to prevent severe hypo- and hyperglycemic events. While continuous glucose monitoring has improved blood glucose management, deploying predictive models on wearable devices remains challenging due to computational and memory constraints. To address this, we propose a novel Lightweight Sequential Transformer model designed for blood glucose prediction in T1D. By integrating the strengths of Transformers' attention mechanisms and the sequential processing of recurrent neural networks, our architecture captures long-term dependencies while maintaining computational efficiency. The model is optimized for deployment on resource-constrained edge devices and incorporates a balanced loss function to handle the inherent data imbalance in hypo- and hyperglycemic events. Experiments on two benchmark datasets, OhioT1DM and DiaTrend, demonstrate that the proposed model outperforms state-of-the-art methods in predicting glucose levels and detecting adverse events. This work fills the gap between high-performance modeling and practical deployment, providing a reliable and efficient T1D management solution.